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Background
Control of mRNA translation is fundamentally altered in cancer. Insulin-like growth factor-I (IGF-I) signaling
regulates key translation mediators to modulate protein synthesis (e.g. eIF4E, 4E-BP1, mTOR, and S6K1).
Importantly the Amplified in Breast Cancer (AIB1) oncogene regulates transcription and is also a downstream
mediator of IGF-I signaling.Materials and Methods
To determine if AIB1 also affects mRNA translation, we conducted gain and loss of AIB1 function experiments in
estrogen receptor alpha (ERα)+ (MCF-7L) and ERα - (MDA-MB-231,MDA-MB-435 and LCC6) breast cancer cells.Results
AIB1 positively regulated IGF-I-induced mRNA translation in both ERα+ and ERα- cells. Formation of the eIF4E-4E-BP1
translational complex was altered in the AIB1 ERα+ and ERα- knockdown cells, leading to a reduction in the eIF4E/4E-BP1
andeIF4G/4E-BP1 ratios. In basal and IGF-I stimulatedMCF-7 andLCC6cells, knockdownof AIB1decreased the integrity of
thecap-binding complex, reducedglobal IGF-I stimulatedpolyribosomalmRNA recruitmentwith a concomitant decrease in
ten of the thirteen genes tested in polysome-bound mRNAs mapping to proliferation, cell cycle, survival, transcription,
translation and ribosome biogenesis ontologies. Specifically, knockdown of AIB1 decreased ribosome-bound mRNA and
steady-state protein levels of the transcription factors ERα and E2F1 in addition to reduced ribosome-bound mRNA of the
ribosome biogenesis factor BYSL in a cell-line specific manner to regulate mRNA translation.Conclusion
The oncogenic transcription factor AIB1 has a novel role in the regulation of polyribosome recruitment and formation of the
translational complex. Combinatorial therapies targeting IGF signaling and mRNA translation in AIB1 expressing breast
cancers may have clinical benefit and warrants further investigation.
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The p160 co-activator factor amplified in breast cancer (AIB1)
human oncogene, also referred to as SRC3, p/CIP, RAC3, ACTR and
TRAM3 has been described as a key pleiotropic “master regulator” of
gene transcription in many types of human cancers [1,2]. Importantly
it is over-expressed in up to 64% of all breast cancers and functions as
downstream mediator of insulin-like growth factor (IGF-I) tyrosine
receptor signaling [3,4]. AIB1 is phosphorylated on serine and
tyrosine residues after the type I IGF receptor (IGF1R) activation by
IGF-I, but the effects of IGF1R signaling on AIB1 function require
further investigation [3,5]. The tumorigenic actions of AIB1 are
driven by its function as a co-regulator of known transcription factors;
estrogen receptor alpha (ERα) in luminal breast cancer or E2F1
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progesterone receptor and human epidermal growth factor receptor 2
negative (HER2)) [6]. IGF1R signaling results in activation of
downstream effectors of the AKT-pathway and MAPK-pathway that
function to control mRNA translation in breast cancer [4,7].
However, the extent to which AIB1 participates in IGF-I stimulated
mRNA translation in breast cancer is not known.
The downstream IGF1R signaling mediator, mammalian target of
rapamycin complex 1 (mTORC1) regulates mRNA translation by
phosphorylation of S6K1 and 4E-binding protein-1 (4E-BP1)
[8–10]. Cap-dependent translation is a highly regulated cellular
process, controlled by the eukaryotic initiation factor 4E (eIF4E), the
scaffold protein eIF4G, the ATP-dependent helicase protein eIF4A,
and eIF4B to collectively form the eIF4F complex which recognizes
the 7-methyl guanosine (m7GTP) cap at the mRNA 5’ terminus
[11]. During cellular stress, such as hypoxia and nutrient deprivation,
a switch from cap-dependent to cap-independent translation occurs
[12]. Hypophosphorylated 4E-BP1 sequesters the rate limiting factor
eIF4E (i.e. inactive translation) until it is phosphorylated by
mTORC1/S6K1 to allow assembly of the eIF4F complex (i.e. active
translation) [13,14]. Moreover, our laboratory has shown that IGF-I
signaling stimulates S6K1 resulting in ERα Ser167 phosphorylation
and estradiol-independent gene transcription [15]. S6K1 also
enhances eIF4B phosphorylation in breast cancer cells
In addition to IGF-I induced post-translational activation of key
translational mediators, assembly of the 43S pre-initiation ribosomal
complex and mRNA ribosome recruitment are required for
cap-dependent translation to occur [11,16–18]. AKT and the
transcriptional mediators, c-MYC and E2F1 have all been reported
to indirectly regulate mRNA cap-dependent translation by transcrip-
tionally affecting expression of ribosomal RNA required for synthesis
of ribosome biogenesis factors [19–22]. Additionally, the oncogenic
actions of Ras and AKT may require increased rates of ribosomal
recruitment [23]. However, whether the well characterized transcrip-
tional mediator, AIB1 also possesses similar functions as described for
c-MYC, E2F1, Ras and AKT is not well known. Since IGF-I
signaling positively regulates mRNA cap-dependent translation and
IGF-I can modulate AIB1 phosphorylation, we hypothesized that
AIB1 possesses both transcriptional and translational functions in
breast cancer.
In this study we examined the functional role of IGF1R signaling
and AIB1 on cap-dependent and cap-independent mRNA translation
in ERα+ and ERα - breast cancer cells. To determine whether AIB1 is
required for ‘active’ mRNA translation we have also studied the
regulatory effects of IGF-I and AIB1 on changes to total and
ribosome-bound mRNA expression of key cancer-related gene targets
associated with breast cancer cell growth (e.g. Ki67 and PCNA [24]),
migration (e.g. VEGFA [25]), cell cycle (e.g. p21 [24]), survival (e.g.
BCL2 [26]), transcription (e.g. ERα, E2F1 and c-MYC [19]),
translational (e.g. eIF4E and 4E-BP1 [11]) and ribosome biogenesis
(e.g. BYSL, eIF5 and eIF2α [16,17,27,28]).
Methods
Reagents
Cell culture media, trypsin, dimethyl sulfoxide (DMSO) and
penicillin and streptomycin (P/S), puromycin and ampicillin
antibiotics, HEPES and SuperSignal®West Pico Chemiluminescent
substrate were purchased from Thermo Fisher Scientific, (Logan, UT,USA). Fetal bovine serum (FBS) was purchased from Atlas Biologicals
(CO, USA), IGF-I from GroPep (Adelaide, AUS) and
NVP-AEW541 (AEW; IGF1R inhibitor) from Novartis Pharma, Inc
(Basel, Switzerland). Insulin was purchased from Lilly (Indianapolis,
IN, USA); complete protease inhibitor cocktail pellets, FuGENE 6
Transfection Reagent and Fast Start Universal SYBR Green Master
(Rox) from Roche Biochemicals (Indianapolis, IN, USA); trace
elements from Corning, CellGro (Manassas, VA, USA); Dual-Glo
luciferase and Lipofectomine 2000 transfection reagents from Promega
(Madison, WI, USA); qScript cDNA SuperMix from Quanta
Biosciences (Gaithersburg, MD, USA); and 7-Methyl (m7) GTP-
Sepharose 4B from GE Healthcare UK Limited.
Antibodies
Primary rabbit polyclonal antibodies SRC-3, total and
phospho-AKTSer473, total and phospho-p70 S6 KinaseThr389,
eIF4G, eIF4E, total 4E-BP1, total and phospho-ERαSer167, P21,
E2F1 and total and phospho-p44/42MAPK Thr202//Tyr204 were
purchased from Cell Signaling. Primary mouse monoclonal antibod-
ies PCNA and B-actin were purchased from Cell Signaling and
Abcam, respectively and secondary anti-rabbit and anti-mouse IgG
horseradish peroxidase-conjugated antibodies from Pierce.
Cell lines and culture
MCF-7L cells, an ER+ cell line, were provided by C. Kent Osborne
(Baylor College of Medicine) and ER- MDA-MB-435, LCC6 (a
metastatic sub-line of the MDA-MB-435 cells) and MDA-MB-231
cells were provided by Robert Clarke (Lombardi Cancer Center,
Georgetown University, Washington, DC, USA). Controversy exists
to the lineage origin of the LCC6 cells as to whether they are in fact
breast cancer or melanoma cells, although recent evidence suggests
that they are of breast origin with a melanocytic phenotype
[16,29,30]. All cell lines were maintained and cultured at 37°C in
5% CO2, 95% air. MCF-7L wild-type and short hairpin (sh)RNA
knockdown cells were grown in DMEM supplemented with 5% FBS
plus 11.25 nM insulin, 100 U/ml penicillin, and 100 μg/ml
streptomycin. MDA-MB-435 and LCC6 wild-type and shRNA
knockdown cells were maintained in DMEM supplemented with
10% FBS plus 11.25 nM insulin, and MDA-MB-231 wild-type and
shRNA cells were maintained in DMEM supplemented with 10%
FBS plus 100 U/ml penicillin and 100 μg/ml streptomycin (P/S).
293T human kidney cells were cultured in phenol-red DMEM
supplemented with 10% FBS plus insulin. Cells were serum deprived
in phenol-red free (PRF)-IMEM (supplemented with 20 mM
HEPES, 1 × trace elements and 2 μg/ml transferrin) for 24 hours
prior to treatment with 5 nM IGF-I or inhibitor (i.e. 0.3 μM AEW).
Inhibitor was added to the cells for 4 hours prior to IGF-I exposure.
Filter sterilized DMSO was added to the media as a control for the
highest concentration used in the inhibitor treatments (i.e. 10 μM).
Preparation and transduction of lentiviral-delivered
short-hairpin RNA
AIB1 and scrambled control shRNA was delivered via pLKO.1
lentiviral vectors (RNAi Consortium, Sigma and Plasmid Repository,
Addgene), which contain the puromycin resistance gene and drives
shRNA expression from the human U6 promoter. The shRNA
plasmids (i.e. shCON (scrambled control), shAIB1 and shAIB1 (3′
UTR)) and their sequences (Suppl. Table 1) were provided by Dr.
Christopher Chien, Department of Oncology, Georgetown
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designed to correspond with nucleotides to the coding region (i.e.
564-582 base pairs) and the shAIB1 (3′UTR) sequence to 40 bases
after the stop codon in the non-coding untranslated region of the
AIB1 mRNA sequence. The shCON scrambled control sequence is
not specific for any target mRNA sequence (Qiagen, Valencia, CA).
The shRNA was used to create MCF-7L, LCC6, and MDA-MB-231
wild type. shCON, shAIB1, and shAIB1 (3′UTR) stably expressing
cells. 2 × 106 293T cells were plated per 10 cm-petri dish, serum
deprived for 24 hours and subsequently transfected using FuGENE 6
transfection reagent in PRF-IMEM with 3 μg of shCON and shAIB1
lentiviral vectors combined with 3 μg pCMV-dR8.2 dvpr packaging
and 0.375 μg pCMV-VSV-G envelope vectors for 6 hours. Media
were replaced and after 48 hours the lentiviral supernatant was
centrifuged and filtered sterilized using a 0.22 μm mixed cellulose
ester syringe (Thermo Fisher Scientific, USA). 1.0 × 106 cells were
plated in 10 cm-petri dishes. The following day the cells were
transduced for 24 hours with 1 ml of the lentivirus supernatant added
to 9ml fresh media supplemented with 8 μg/ml polybrene. 2–10 μg/ml
of puromycin was added for cell selection.
Dual reporter gene assay
8 × 104 MCF-7L and 6 × 104 MDA-MB-231 and LCC6 cells
were serum deprived in PRF-IMEM supplemented with 5%
dextran-coated charcoal (DCC)-FBS plus P/S for 24 hours and
cultured overnight in 24-well dishes (five replicates per treatment).
The media were replaced with fresh PRF-IMEM, and wild-type or
stably expressing MCF-7L cells were transiently transfected using
Lipofectamine 2000. MDA-MB-231, MDA-MB-435, and LCC6
cells using FuGENE 6 with 250 ng/well of bi-cistronic reporter
expression construct (pCDNA3-renilla-LUC-IRES-firefly-LUC),
courtesy of V. Polunonvsky (Masonic Cancer Center, University of
Minnesota), in addition to 250 ng/well of pCDNA.3-empty vector
(i.e., EV) and 250 ng/well of pCDNA.3-AIB1 (i.e., AIB1) expression
vectors for 24 hours. The bi-cistronic vector measures cap-dependent
translation (renilla luciferase: rLUC) and cap-independent translation
(firefly luciferase; fLUC). Post-transfection, the media were replaced
with PRF-IMEM +/− 5 nM IGF-I for 24 hours. Luciferase
relative light units (RLU) were measured on a Bio-Tek Synergy
2 luminometer and Gen5 software using a Dual-Glo luciferase
assay system.
Immunoblot
Protein lysates were prepared and concentrations determined
as previously described [15]. 40 μg total protein was boiled at 95 °C
for 5 minutes and run on SDS-PAGE, transferred to nitrocellulose
and probed with antibodies to detect phospho- and/or total-AIB1,
AKT, S6K1, MAPK, eIF4G, eIF4E, 4E-BP1, E2F1, ERα, P21,
and PCNA steady-state protein levels per the manufacturer’s
immunoblot protocol.
m7GTP agarose bead micro-scale affinity chromatography and
densitometry
2 × 106 MCF-7L shCON and shAIB1 cells were plated in a 1 ×
150-mm-diameter petri dish and grown to approximately 70%
confluence in culture medium. The cells were serum starved in
PRF-IMEM (plus additives) for 24 hours and subsequently replaced
with fresh PRF-IMEM (plus additives) +/− 5nM IGF-I for 24 hours.
Protein lysates were prepared and m7GTP cap-binding assay wasperformed as previously described [15,31]. 450 μg total-protein was
used for the m7GTP agarose bead micro-scale affinity chromatog-
raphy and 40 μg for separate immunoblot analysis to detect phospho-
and/or total-AIB1, AKT, S6K1, MAPK, eIF4G, eIF4E and 4E-BP1
steady-state protein levels. Measurement of m7GTP cap-binding
immunoblot protein intensity was performed using densitometry
(Bio Rad GS-700 Densitometry Gel Doc) to calculate the eIF4G/
4E-BP1 and eIF4E/4E-BP1 ratios as a representation of a relative
translational index (arbitrary values) similar to published ratio
calculations [32].
Polyribosome preparation and RNA extractions
MCF-7L and LCC6 shCON and shAIB1 cells were used to evaluate
the effect of AIB1 on polysome recruitment in ER+ and ER- cells. 2 ×
106 cells were plated in 6 × 150-mm-diameter petri dishes and serum
deprived for 24 hours in PRF-IMEM (plus additives). Subsequently
the medium was either replaced with fresh PRF-IMEM (plus additives)
+/− 5nM IGF-I and incubated for an additional 24 hours. Polysome
purification was performed as previously described [33,34]. Total-RNA
and RNA from individual polysome fractions were purified using
Trireagent (Sigma-Aldrich) following the manufacturer’s protocol.
RNA pellets were re-suspended in nuclease-free H2O and concentra-
tions weremeasured using a plate reader (BioTek, Synergy 2) at a 260/280
nm wavelength absorbance ratio.
Reverse-transcription and quantitative-real-time polymerase
chain reaction
Reverse-transcription of 1 μg RNA per individual sample was
performed using Transcriptor First Strand cDNA Synthesis Kit
(Roche) and qRT-PCR using FastStart Universal SYBr Green Master
(Rox) according to manufacturer’s standard protocol. Absolute
quantification of RNA copy number was generated using a standard
curve of arbitrary concentrations and melting curve analysis using
RealPlex4, MasterCycler epgradientS and epMotion 5070 (BioRad).
Primer design was performed using http://www.ncbi.nlm.nih.gov/
pubmed gene analysis apart from P21 and PCNA were obtained from
published research [24] (Suppl. Table 1).
Statistical analysis
A one-way analysis of variance (ANOVA) (GraphPad Prism,
version 5.01, GraphPad Software, San Diego, CA, USA) was used to
assess statistical significance between treatment samples in the
reporter gene assay, polyribosome fractionation assay and qRT-PCR
experimental studies. Statistical significance was accepted *P b .05,
**P b .01. ***P b .001.
A weighted average calculation was performed to determine the
average distribution of RNA across the gradient fractions following
IGF stimulation and AIB1 shRNA knock-down. An overall
re-distribution of the RNA to the right (or left) indicates a
quantitative increase (or decrease) in translation activity.
Results
AIB1 induced cap-dependent and cap-independent mRNA
translation
To determine if AIB1 functions as a positive mRNA translational
regulator similar to c-MYC, E2F1 and AKT [19], an AIB1 expression
vector was transiently transfected into breast cancer cells. ER+ and
ER- breast cancer cells were studied as AIB1 is over-expressed in both
luminal and basal breast cancer [3,4]. Cap-dependent and -independent
Neoplasia Vol. 18, No. 2, 2016 Amplified in Breast Cancer in Breast Cancer Cells Ochnik et al. 103translation was measured using a bi-cistronic reporter construct. IGF-I
stimulated cap-dependent (Figure 1A) and cap-independent (Figure 1B)
translation in MCF-7L, MDA-MB-231, and MDA-MB-435 cells. InFigure 1. Over-expression and knockdown of AIB1 regulates cap-
independent mRNA translation was measured using a bi-cistronic re
rLUC) and cap-independent (i.e. firefly luciferase; fLUC) translation wa
following pCDNA3-EV (EV; empty boxes) and pCDNA3-AIB1 (AIB1; b
IGF-I for 24 hours.C and D) MCF-7L cells were infected with sh
cap-dependent and cap-independent translation was measured. IGF-I
shRNA scrambled control (shCON) or AIB1 (shAIB1) and cap-depende
was for 24 hours.Luciferase expression (rLUC and fLUC) is depicted on
**P b .01. ***P b .001 one-way ANOVA. Experiments were preforme
from MCF-7L, 231 and 435 cells, and the individual shCON and shA
following IGF-I treatment for 24 hours are shown as insets. All proteall three cell lines AIB1 expression increased both cap-dependent
(Figure 1A, black boxes) and cap-independent translation (Figure 1B,
black boxes) in control and IGF-I treated cells compared to emptydependent and cap-independent translation. Cap-dependent and
porter gene assay. A and B) Cap-dependent (i.e. renilla luciferase;
s measured in MCF-7L, MDA-MB-231 (231) and MDA-MB-435 (435)
lack boxes) vector transfection. Cells were treated with or without
RNA scrambled control (shCON) or AIB1 (shAIB1 (3′UTR)) and
treatment was for 24 hours.E and F) LCC6 cells were infected with
nt and cap-independent translation was measured. IGF-I treatment
the graphs as relative light units (RLU). Error bars are SEM *P b .05,
d three times. Immunoblot analysis performed on protein lysates
IB1 cell-lines to measure endogenous levels of AIB1 protein levels
in samples were run on the same gel.
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eliminated in all AIB1-transfected cell lines by treatment with an IGF1R
tyrosine kinase inhibitor AEW541 (P b .05; data not shown).
Immunoblot analysis was performed to show that all cell-lines expressed
endogenous AIB1 under basal and IGF-I treated experimental
conditions and were therefore suitable for our studies (Figure 1B
inset). MCF-7L AIB1-transfected protein cell lysates demonstrated
effective AIB1-transfection by an increase in AIB1 steady-state protein
expression levels compared to EV-transfected cells (data not shown).
A significant reduction of both cap-dependent and independent
expression was seen when AIB1 levels were suppressed by shRNA in
MCF-7L (Figure 1, C and D) and LCC6 cells (Figure 1, E and F) at
all levels of AIB1 expression (EV and AIB1-transfected cells). Our
findings were further validated using a different shAIB1 knockdown
vector in MCF-7L cells and in the MDA-MB-231 shAIB1 cells (P b
.01; Suppl. Figure 1, A and C; cap-dependent and Suppl. Figure 1, B
and D; cap-independent). Immunoblot analysis confirmed effective
shRNA knock-down of AIB1 by decreased levels of AIB1 protein in
cell lines infected with the shAIB1 construct (Figure 1, D and F and
Suppl. Figure 1, B and D insets). Collectively, these data provide
evidence that IGF-I induced mRNA translation is positively
modulated by the translational mediator AIB1.
AIB1 suppression altered the integrity of the eIF4F
translational complex
To further determine how AIB1 regulates IGF-I induced mRNA
cap-dependent translation we measured protein levels of the PI3K and
MAPK signaling pathway and key translational mediators. Cells
transfected with a scrambled shRNA control (shCON) and shAIB1
MCF-7L and LCC6 cells were treated +/− IGF-I for 24 hours and
protein cell lysates were used for immunoblot analysis. In MCF-7L
IGF-I induced phosphorylation of key proteins pAKT, pS6K1,
pMAPK, and p4E-BP1 within 10 minutes and persisted for up to 24
hours (Figure 2A). This effect was seen for pAKT and p4E-BP1 in the
LCC6 cell line (Figure 2B). However, in these cells pS6K1 and pMAPK
were constitutively activated even in the absence of growth factor
stimulation (Figure 2B). Moreover, following 24 hours of IGF-I
treatment, pS6K1 was decreased with an accompanying increase in
total-S6K1 protein in LCC6 shAIB1 cells (Figure 2B). Conversely,
decreased pAKT and pMAPK protein was seen after 24 hours of IGF-I
treatment in the shAIB1 MCF-7L cells (Figure 2A). Most notably and
relevant to the translational function of AIB1, the protein levels of
hypo-phosphorylated 4E-BP1 were higher in shAIB1 cells compared to
control cells in both MCF-7L and LCC6 cells (Figure 2, A and B).
Similar changes to 4E-BP1 protein levels were noted using the shAIB1
(3′UTR) MCF-7L and LCC6 cells (Suppl. Figure 2, A and B).
m7GTP agarose bead micro-scale affinity chromatography (i.e.
cap-binding assay) was employed to determine if AIB1 levels altered
recruitment and the assembly of the eIF4F translational complex to
the mRNA m7GTP cap required for ‘active’ translation. In the
absence of IGF-I we observed an increase in eIF4E-4E-BP1
(hypo-phosphorylated) protein bound to the m7GTP in shAIB1
compared to the shCON cells (Figure 2A) which in effect leads to
‘inactive’mRNA translation. As expected, IGF-I treatment resulted in
decreased levels of 4E-BP1 bound to the m7GTP cap in both the
shCON and shAIB1 MCF-7L cells reflecting 4E-BP1 phosphoryla-
tion and the release of eIF4E required for ‘active’ mRNA translation.
eIF4G was seen to be bound to the m7GTP cap at a higher amount
following 24 hours of IGF-I treatment in control cells, compared tothe shAIB1 cells suggesting that AIB1 was necessary for optimal
recruitment of the eIF4F complex to the m7GTP cap (Figure 2A).
More-over basal levels of the eIF4G/4E-BP1 and eIF4E/4E-BP1
ratios were decreased in the shAIB1 compared to shCON cells most
notably at 24 hours (Figure 2, C and D). These ratio changes reflect a
higher proportion of hypo-phosphorylated 4E-BP1 bound to the
m7GTP cap compared to the translational modulators, eIF4E and
eIF4G in the shAIB1 cells compared to the shCON cells potentially
leading to a ‘brake’ on active mRNA translation. These data suggest
AIB1 loss may suppress ‘active’ mRNA translation. Further studies
investigating whether AIB1 directly interacts with 4E-BP1, eIF4F or
other translational mediators such are required.
Reduction in AIB1 expression reduced IGF-I induced mRNA
polyribosomal recruitment
Our initial reporter gene assay findings suggested that AIB1 is an
IGF-I downstream translational mediator. To further support this
finding, the effect of AIB1 on IGF-I induced mRNA polyribosome
recruitment was directly studied [20,23]. Polyribosomes were isolated
from control and 24 hours IGF-I treated MCF-7L and LCC6
shCON and shAIB1 cells to determine changes to total and
ribosome-bound mRNA of key translational, transcriptional, migra-
tion, cell cycle, proliferation, and ribosome biogenesis mediators.
IGF-I treatment increased the absolute amount of ribosome-bound
mRNA in both the shCON and shAIB1 MCF-7L cells (Figure 2E).
IGF-treatment led to a strong 0.7 unit left to right shift in the weighted
average fraction distribution of ribosome-boundmRNA in the shCON
cells, indicating increased global ribosomal loading (P b .05; Figure 2F)
but this shift was diminished in the shAIB1 cells (Figure 2G). The
overall distribution of ribosome bound mRNA was similar in the
absence of IGF-I in the shCON and shAIB1 cells (Figure 2H).
Importantly, when AIB1 was suppressed, IGF-I treatment resulted in a
0.5 unit right to left shift of the weighted average fraction distribution of
ribosome-bound mRNA, reflecting that AIB1 is necessary for normal
translation levels (Figure 2I). We further conducted proof-of-principle
experiments using the LCC6 cell line. There were no differences in the
amount of ribosome-boundmRNA following IGF-I treatment in either
the shCON or shAIB1 LCC6 cells most likely due to the constitutive
activation of S6K1 and MAPK in these cells (Figure 2A and Suppl.
Figure 3, A–C). However consistent with the MCF-7L cells, AIB1
knockdown reduced the overall transcript ribosome loading, leading to
a left to right shift in the weighted average fraction distribution of
ribosome-boundmRNA in the absence (i.e. 0.7 unit) and presence (i.e.
0.5 unit) of IGF-treatment (Suppl. Figure 3, D and E).
To evaluate whether AIB1 and IGF-I affected expression of key
breast cancer genes we studied mRNA expression levels in the total
mRNA and ribosome bound mRNA fractions by quantitative
real-time PCR. In MCF-7L cells, shAIB1 decreased AIB1 total
mRNA by approximately 50% and ribosome-bound AIB1 mRNA
was also reduced (P b .05; Figure 3A). Moreover, we classified genes
into specific groups based on total-mRNA expression and identified
that the mRNA transcript levels of eIF4E, VEGFA, Ki67, and BYSL
were IGF-I- and AIB1-dependent defined by the lack of significant
IGF-I induction of gene expression in the shAIB1 cells (P b .05;
Figure 3, B–E), E2F1 and PCNA were classified as IGF-dependent
and AIB1-independent (P b .05; Figure 3, F and G), ERα and P21
were classified as IGF-independent and AIB1-dependent (P b .05;
Figure 3, H and I) and 4E-BP1, BCL2, c-MYC, eIF5 and eIF2α
were classified as IGF-1 and AIB1-independent (Figure 4, A–E).
Figure 2. AIB1 knockdown increases eIF4E and 4E-BP1 complex steady-state protein levels and reduces polyribosome recruitment. A)
Micro-scale affinity chromatography using m7GTP agarose beads (top) was performed using shRNA scrambled control (shCON) or AIB1
(shAIB1) IGF-I treated MCF-7L cell protein lystates. Immunoblot analysis was performed on whole cell protein lysates (bottom).
Hyper-phosphorylated (hyper-P; top bands) and hypo-phosphorylated (hypo-P; lower bands) of 4E-BP1 are depicted on the immunoblot
images in A and B.B) Immunoblot analysis was performed onwhole cell protein lysates obtained from shCONand shAIB1 LCC6 IGF-I treated
cells.C andD)Densitometrywasperformedon them7GTPcap-binding assayMCF-7L immunoblots to determine a relative translational index
by calculating the eIF4G/4E-BP1 and eIF4E/4E-BP1 ratios of control cells for 10 minutes and 24 hours.E) Densitometry (O.D.254) traces of
polysome preparations. 107 shCON and shAIB1 MCF-7L cells were serum starved in PRF-media (plus additives) for 24 hours and
subsequently treated +/− 5 nM IGF-I for 24 hours. Total RNA was isolated, loaded onto sucrose gradients, ultracentrifuged to stratify the
ribosome bound mRNA transcripts based on the number of bound ribosomes, and fractionated into 10 fractions. Fraction 10 represents
transcriptswith themost bound ribosomes. Free ribosomal subunits (40Sand60S),monosomes (80S) and the polysomalmRNA fractions are
depictedon the densitometry trace readings.F-I) PercentmRNAper individual fraction normalized to total polysomeboundRNA. Experiments
wereperformed three timeswith similar results; graphs represent combineddata from twoexperiments. Error bars areSEM*Pb .05 one-way
ANOVA. A weighted average calculation was performed to demonstrate an overall shift in the average number of bound ribosomes.
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revealed that the majority of target genes, ten of the thirteen measured
in our study were positively regulated by IGF-I and AIB1 (i.e. eIF4E,VEGFA, Ki67, BYSL, E2F1, PCNA, ERα, P21; Figures 3, B–I and
4E-BP1 and eIF2α; Figure 4A and B). Further testing of the ten genes
revealed that ribosomal loading was reduced in the heavy mRNA
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cells. Moreover, in the absence of IGF-I, an additional reduction in
ribosomal loading was observed in the four genes VEGFA, BYSL,
ERα and P21. Of the remaining three genes c-MYC, BCL-2 and
eIF5 IGF-I treatment led to a negative regulation of ribosomal
recruitment most notably in the heavy fractions (Figure 4, C–E).
Immunoblot analysis confirmed our findings by the reduction of total
and pERα, E2F1, P21 and PCNA steady-state protein levels in the
AIB1 knock-down MCF-7L cells (Figure 4F).
Lastly, to validate our findings we tested five genes using the total
and polysome fractionated mRNA samples obtained from shCON
and shAIB1 LCC6 cells. Total and ribosome bound AIB1 mRNA was
reduced by approximately 80% in the control and IGF-I treated
shAIB1 vs. shCON cells (Suppl. Figure 3F). We identified an
IGF-I-independent and AIB1-dependent gene transcriptional regu-
lation of 4E-BP1, E2F1 and BYSL, yet eIF4E was not significantly
affected by either IGF-I or AIB1 (P b .05; Suppl. Figure 3, G–J). A
reduction in the ribosome loading of 4E-BP1 and E2F1 mRNA was
evident under control and IGF-I treatment conditions (Suppl. Figure
3G and H), yet eIF4E mRNA was slightly increased by IGF-I
treatment following AIB1 knockdown (Suppl. Figure 3J). We
observed a reduction of ribosome-bound BYSL mRNA of the heavier
fractions in the control AIB1 knockdown cells (Suppl. Figure 3I).
Collectively, our findings support our hypothesis that AIB1
influences both gene transcription and mRNA translation and
provides evidence that AIB1 potentially modulates ribosomal
recruitment on a subset of cancer-related genes in a cell-line
specific manner.
Discussion
Our previous work has shown that IGF-I signaling affects gene
transcription in breast cancer cells via its ability to activate PI3K/
mTORC1/S6K signaling [15]. These pathways are also involved in
enhanced mRNA cap dependent translation [11] and it seemed
likely that the IGF-I downstream transcriptional mediator, onco-
genic factor AIB1 would stimulate both transcription and
translation. Here we show for the first time a role for AIB1 in the
control of mRNA cap-dependent and cap-independent in breast
cancer cells. While AIB1 clearly participates in IGF-I mediated
effects, we also show that AIB1 influences gene expression
independently of IGF-I signaling.
The translational machinery (eIF4F) components, 4E-BP1, eIF4E,
and eIF4G are over-expressed in many different types of cancer and
have been found to be oncogenic [11,12,32]. Given these oncogenic
properties, it follows that the oncogene AIB1 also participates in
enhancing mRNA translation. The translational activator eIF4E has
become an attractive cancer therapy target for inhibitor therapies
including: the antisense oligonucleotide 4E-ASO, the small molecule
inhibitor, 4EGI-l and the antiviral drug ribavirin [11,32]. AnFigure 3. AIB1 knockdown reduces recruitment of IGF-I induced targ
and fractionated mRNA samples following polysomal fractionation o
(shCON) and AIB1 (shAIB1) MCF-7L cells. Primers were used as prob
light (1-6; lower percentage of ribosome-bound mRNA) and heavy
fractions; A) AIB1, B) eIF4E, C) VEGFA, D) Ki67, E) BYSL, F) E2F1,
performed with similar results. Graphs for total RNA depict three trea
.01, ***P b .001 one-way ANOVA. Independent examples of a singl
RPLPO primers were used as a control for each gene examined. The
reference gene normalized to RPLPO.inhibitor of mTORC1 has been approved for the treatment of
endocrine resistant breast cancer [35] which certainly influences cap
dependent translation. More specific inhibitors of translation are
being tested in clinical trials; the translational inhibitor ribavirin is
currently being tested as a monotherapy in an ongoing Phase I and II
clinical trial (NCT01309490) for solid cancers including breast
cancer highlighting the potential therapeutic impact of inhibiting
mRNA translation [36]. Recently it has been reported that activated
mRNA translation is a promoting factor in driving therapy resistance
in melanoma [37].
Targeting of ER with selective ER-modulators (tamoxifen, fulves-
trant) to reduce its activity and aromatase inhibitors (letrozole,
anastrozole, and exemestane) to reduce estrogen levels has been a
successful therapeutic strategy. Given that clinical approaches are
determined by ER expression and activity in breast cancer, the novel
insights relating to the molecular regulation of ER by AIB1 revealed in
this study have important clinical implications for ER-positive disease.
In light of our findings, it is plausible that AIB1, like c-MYC, acts as a
translational regulator by the formation of a transcriptional complex
with ERα on promoter regions of ribosome biogenesis genes required
for translation [19–22] and this crosstalk could serve as an additional
therapeutic target that would affect both ERα and ribosomal function.
Success of themTORC1 inhibitor, everolimus, in the treatment of ER+
breast cancer supports this possibility [35]. Based on our findings a
similar effect may occur in the LCC6 cells by AIB1 forming a
transcriptional complex with E2F1. It is tempting to speculate that
AIB1 indirectly regulates c-MYC activity via AKT and E2F1 signaling
pathways, as recently reported in bladder cancer to aid in its translational
regulation in specific molecular subtypes of breast cancer [22,23,38].
It is now becoming increasing evident that in conjunction with the
PI3K/AKT/mTORC1 and Ras signaling hubs, that transcriptional
factors such as C-MYC co-operate in a finely tuned cellular process to
regulate protein synthesis via activation of polymerase I and II
ribosomal RNA (rRNA) synthesis and subsequent production of
ribosome biogenesis factors [20,39]. Our study demonstrates novel
findings that in addition to C-MYC, over-expression of AIB1 may
function in a similar manner to fuel cancer cells by transcriptionally
increasing rates of rRNA and production of ribosome biogenesis
machinery. Clinically our findings are relevant to the development of
novel and more effective IGF1R-targeted cancer therapies in line with
a recent study that has shown a synergistic effect of co-targeting
ribosome biogenesis using a Phase I novel small molecule inhibitor,
CX561 and mRNA translation using the mTORC inhibitor,
everolimus in MYC-driven lymphoma l [40,41].
In support of our results, in vitro inhibition of 4E-BP1 function
increases the malignant phenotype in breast cancer cells [42] and
over-expression of hypo-phosphorylated 4E-BP1 results in a reduction
of breast cancer cell proliferation [43]. Furthermore, our findings
demonstrating an altered ratio of key eIF4F translational mediators, in aet mRNA to polysomes. qRT-PCR analysis was performed on total
batined from lentiviral stably expressing shRNA scrambled control
es to measure relative changes in gene expression of total RNA in
(7-10; higher percentage of ribosome mRNA) pooled ribosomal
G) PCNA, H) ERα and I) P21. Three replicate experiments were
tment and technical replicates. Error bars are SEM *P b .05, **P b
e experiment for each gene are shown of the ribosomal fractions.
graphs represent the mRNA copy number (arbitrary value) of each
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Figure 4. AIB1 regulates polyribosome recruitment to cancer-related targets. qRT-PCR analysis was performed on total and fractionated
mRNA samples following polysomal fractionation obatined from lentiviral stably expressing shRNA scrambled control (shCON) and AIB1
(shAIB1) MCF-7L cells. Primers were used as probes to measure relative changes in gene expression of total RNA and in light (1-6; lower
percentage of ribosome-bound mRNA) and heavy (7-10; higher percentage of ribosome-bound mRNA) pooled ribosomal fractions; A)
4E-BP1, B) eIF2α, C) c-MYC, D) BCL2 and E) eIF5. Graphs for total RNA depict three treatment replicates comprised of three technical
replicates. Error bars are SEM. Independent examples of a single experiment for each gene are shown of the ribosomal fractions. RPLPO
primers were used as a control for each gene examined. The graphs represent the mRNA copy number (arbitrary value) of each reference
gene normalized to RPLPO.F) Immunoblot analysis was performed on protein lysates obatined from shCON and shAIB1 MCF-7L cells.
Total MAPK was used as a loading control.
108 Amplified in Breast Cancer in Breast Cancer Cells Ochnik et al. Neoplasia Vol. 18, No. 2, 2016reduced AIB1 protein cellular context, complement reports that a high
eIF4E/4E-BP1 ratio is associated with a better clinical prognosis in
luminal A breast cancer subtypes [32] suggesting a role for cap
dependent translation in the ERα expressing subset of breast cancers.
Our findings provide new evidence that AIB1may function to promote
mRNA translation of cancer-associated genes in part by increasing
mRNA ribosomal recruitment and thus the rate of translation initiation.
Conclusions
IGF-I signalling in breast cancer has been supported by preclinical
and population data but inhibitors of IGF-I action have been
disappointing in clinical trials [44]. The inability to develop or testspecific biomarkers of “IGF-driven” breast cancers may have
contributed to the relatively limited benefit of IGF-I receptor
inhibitors. Our data suggest that AIB1 expressing breast cancers may
identify a subgroup of breast cancer sensitive to IGF-I signaling
inhibition as multiple genes are transcriptionally regulated by the
combined effects of enhanced signaling and AIB1 function.
Furthermore, combined targeting of IGF-I signaling and AIB1
function might be a useful therapeutic strategy in breast cancer.
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